- Price
- $112.45
- Day
- +2.53%
- Mkt Cap
- $13.34B
- 52W Range
- $61.23 – $112.66
- Volume
- 10.18M
- Beta
- 0.88
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033PR NewswireSAN DIEGO, Sept. 17, 20
Read full article
Bank of America Corp DE purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,740,561 shares of the biopharmaceutical company's stock, valued at approximately $214,504,000. Bank of America Corp DE owned
Read full article
SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the "Convertible Notes").
Read full article
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Read full article
Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Read full article
SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the "Convertible Notes").
Read full article
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read full article
Unlock your portfolio value by investing in high earnings yield stocks like Ternium, Halozyme, POSCO and Talos Energy.
Read full article
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $107.24, for a total value of $2,144,800.00. Following the sale, the chief executive officer directly owned 767,780 shares of the
Read full article
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company's stock, valued
Read full article
Squarepoint Ops LLC cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 40.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 37,035 shares of the biopharmaceutical company's stock after selling 25,257 shares during the quarter. Squarepoint Ops LLC's holdings
Read full article
VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,100 shares of the biopharmaceutical company's stock, valued at approximately $1,025,000. Other large
Read full article